No Data
SymbolStock Name
Latest PriceChg%ChgVolumeTurnoverOpenPre CloseHighLowMarket CapFloat CapSharesShs Float5D %Chg10D %Chg20D %Chg60D % Chg120D %Chg250D %Chg% Year-to-dateDiv YieldTTMTurnover RatioP/E (TTM)P/E (Static)AmplitudeIndustry
US OptionsDetailed Quotes
LIVN240517C65000
- 1.20
- 0.000.00%
15min DelayTrading May 3 15:13 ET
0.00High0.00Low
0.00Open1.20Pre Close0 Volume33 Open Interest65.00Strike Price0.00Turnover38.62%IV6.68%PremiumMay 17, 2024Expiry Date0.00Intrinsic Value100Multiplier8DDays to Expiry1.20Time Value100Contract SizeAmericanOptions Type0.2803Delta0.0908Gamma32.18Leverage Ratio-0.0764Theta0.0040Rho9.02Eff Leverage0.0323Vega
Intraday
- 5D
- 1D
News
Calculating The Intrinsic Value Of LivaNova PLC (NASDAQ:LIVN)
Key Insights The projected fair value for LivaNova is US$78.84 based on 2 Stage Free Cash Flow to Equity With US$64.15 share price, LivaNova appears to be trading close to its estimated fair value
LivaNova First Quarter 2024 Earnings: Revenues Beat Expectations, EPS Lags
Analysts' Opinions Are Mixed on These Healthcare Stocks: Bausch + Lomb Corporation (BLCO), 10x Genomics (TXG) and LivaNova (LIVN)
LivaNova Is Maintained at Neutral by Baird
LivaNova Is Maintained at Neutral by Baird
Express News | Baird Maintains Neutral on LivaNova, Raises Price Target to $66
Express News | LivaNova PLC : Mizuho Raises Target Price to $80 From $75
Comments
LivaNova's share price and revenue have been falling for five years, worrying investors. However, the CEO's modest pay could be a positive. The company's future growth is uncertain.
Investors in LivaNova (NASDAQ:LIVN) Have Unfortunately Lost 45% Over the Last Five Years 1
The company's low P/S, despite strong revenue growth, is tied to weaker future revenue forecasts compared to the industry, deterring investors, which hinders the P/S ratio from increasing. A rise in future revenue is needed to justify a higher P/S ratio.
With a continuous trend of declining ROCE, LivaNova's growth seems doubtful. Under competitive pressures and being a matured enterprise, suggestions lean towards considering other investment options.
Upgrades
• $Banc of California(BANC.US$: Raymond James Upgrades to Outperform from Market Perform - PT $22
• $Cullen/Frost Bankers(CFR.US$: Raymond James Upgrades to Outperform from Market Perform
• $W.W. Grainger(GWW.US$: Wolfe Research Upgrades to Outperform from Peerperform
• $Invitation Homes Inc(INVH.US$: Evercore ISI Upgrades to Outperform from In Line - PT $46 (from $44)
• $PCB Bancorp(PCB.US$: Raymond James Upgrades to Outperform from Market Perfor...
• $Banc of California(BANC.US$: Raymond James Upgrades to Outperform from Market Perform - PT $22
• $Cullen/Frost Bankers(CFR.US$: Raymond James Upgrades to Outperform from Market Perform
• $W.W. Grainger(GWW.US$: Wolfe Research Upgrades to Outperform from Peerperform
• $Invitation Homes Inc(INVH.US$: Evercore ISI Upgrades to Outperform from In Line - PT $46 (from $44)
• $PCB Bancorp(PCB.US$: Raymond James Upgrades to Outperform from Market Perfor...
7
Read more